MALLIK AMEET
Transaction: 06/30/2026
BUY
Change
+675,000
Price
Not reported
Filing
07/02/2026
Type
BUY
ADC Therapeutics S.A.
ADCT • Biotechnology
$1.52
— 0.00 (0.00%)
Current price
EarningsLatest report: Jun 30, 2026
HIGHER-RISK PROFILECautionConfidence: 70%
Quantitative profile — not an investment recommendation.
Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$234.96M
Growth
—
Cash Flow
0/5
Trend
Negative
Evidence
Positive revenue growth · 9.7%Healthy liquidity · 4.37Weak profitability
Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:22 PM UTC
Company Snapshot
Key valuation, quality, financial strength, momentum and analyst data.
Price$1.52
Change0.00%
Shares Out154.58M
Market Cap$234.96M
Enterprise Value$432.96M
52W Range0.78 - 4.98
Beta1.84
P/E-2.42
P/S2.98
P/B-1.03
P/FCF-2.30
EV/Sales5.48
Price$1.52
Change0.00%
Shares Out154.58M
Market Cap$234.96M
Enterprise Value$432.96M
52W Range0.78 - 4.98
Beta1.84
P/E-2.42
P/S2.98
P/B-1.03
P/FCF-2.30
EV/Sales5.48
EV/EBITDA-6.03
EV/FCF-4.23
Earnings Yield-41.24%
FCF Yield-43.55%
Dividend Yield0.00%
Gross Margin90.57%
Oper. Margin-133.21%
Profit Margin-175.31%
Debt/Eq-2.36
Current Ratio4.37
Quick Ratio4.31
Target$3.50
Target Upside130.26%
Target Median$3.50
Target Range2.00 - 5.00
Volume2.13M
Avg Volume1.58M
EPS Surprise-0.02
Investment DNA
How strong this company looks for long-term investors
48
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
70/100
Growth Potential
Revenue and expansion
94/100
Price Attractiveness
Cheap or expensive today
57/100
Why this score▼
Positive revenue growth · 9.7%Healthy liquidity · 4.37Weak profitability
Analyst view
Analyst sentiment and price target
Analyst sentiment
Based on 12 analyst votes · 2026-10-20
67/100
Neutral
Bullish
5
Hold
6
Bearish
1
Price Target
2026-08-14
Low
$2.00
Mean
$3.50
Median
$3.50
High
$5.00
Insider Transactions
Recent executive and insider activity
⚠ 5 high-volume insider sells detected
Carmona Jose
Transaction: 06/30/2026
BUY
Change
+203,700
Price
Not reported
Filing
07/02/2026
Type
BUY
GRAHAM PETER J
Transaction: 06/30/2026
BUY
Change
+221,100
Price
Not reported
Filing
07/02/2026
Type
BUY
| Insider | Type | Change | Price | Transaction | Filing |
|---|---|---|---|---|---|
| MALLIK AMEET | BUY | +675,000 | Not reported | 06/30/2026 | 07/02/2026 |
| Carmona Jose | BUY | +203,700 | Not reported | 06/30/2026 | 07/02/2026 |
| GRAHAM PETER J | BUY | +221,100 | Not reported | 06/30/2026 | 07/02/2026 |
| Zaki Mohamed | BUY | +213,900 | Not reported | 06/30/2026 | 07/02/2026 |
| Redmile Group, LLC | SELL | -2,529,491 | $3.28 | 04/02/2026 | 04/02/2026 |
| Redmile Group, LLC | SELL | -162,517 | $3.80 | 04/01/2026 | 04/02/2026 |
| Redmile Group, LLC | SELL | -188,407 | $3.75 | 03/31/2026 | 04/02/2026 |
| MALLIK AMEET | SELL | -103,231 | $3.99 | 02/13/2026 | 02/18/2026 |
| Carmona Jose | SELL | -25,880 | $3.99 | 02/13/2026 | 02/18/2026 |
| GRAHAM PETER J | SELL | -33,294 | $3.99 | 02/13/2026 | 02/18/2026 |
| Zaki Mohamed | SELL | -24,603 | $3.99 | 02/13/2026 | 02/18/2026 |
| Kallebo Lisa Michelle | SELL | -5,433 | $3.99 | 02/13/2026 | 02/18/2026 |
| Carmona Jose | SELL | -53,236 | $3.29 | 12/06/2025 | 12/09/2025 |
| GRAHAM PETER J | SELL | -49,508 | $3.29 | 12/06/2025 | 12/09/2025 |
| Kallebo Lisa Michelle | SELL | -7,140 | $3.29 | 12/06/2025 | 12/09/2025 |
| Zaki Mohamed | SELL | -41,068 | $3.29 | 12/06/2025 | 12/09/2025 |
| MALLIK AMEET | SELL | -233,146 | $3.29 | 12/06/2025 | 12/09/2025 |
| Redmile Group, LLC | BUY | +3,846,153 | Not reported | 10/27/2025 | 10/28/2025 |
| Azelby Robert | SELL | -12,600 | $3.58 | 06/13/2025 | 06/17/2025 |
| BIZZARI JEAN-PIERRE | SELL | -12,600 | $3.58 | 06/13/2025 | 06/17/2025 |